Skip to content

Cyclophosphamide

Cyclophosphamide, Cytoxan, Cytoxan (lyophilized), Lyophilized Cytoxan (cyclophosphamide) is a small molecule pharmaceutical. Cyclophosphamide was first approved as Cyclophosphamide on 1982-01-01. It is used to treat b-cell chronic lymphocytic leukemia, bcr-abl positive chronic myelogenous leukemia, breast neoplasms, burkitt lymphoma, and endometrial neoplasms amongst others in the USA. Cyclophosphamide's patents are valid until 2036-02-15 (FDA).
Trade Name Cyclophosphamide, Cytoxan, Cytoxan (lyophilized), Lyophilized Cytoxan
Common Name Cyclophosphamide
Indication b-cell chronic lymphocytic leukemia, bcr-abl positive chronic myelogenous leukemia, breast neoplasms, burkitt lymphoma, endometrial neoplasms, ewing sarcoma, granulomatosis with polyangiitis, hemolytic anemia autoimmune, hemosiderosis, hodgkin disease, lung neoplasms, lupus nephritis, multiple myeloma, multiple sclerosis, myasthenia gravis, mycosis fungoides, myeloid leukemia acute, nephrotic syndrome, neuroblastoma, ovarian neoplasms, precursor cell lymphoblastic leukemia-lymphoma, pure red-cell aplasia, retinoblastoma, rhabdomyosarcoma, rheumatic diseases, testicular neoplasms, thrombocytopenic purpura idiopathic, waldenstrom macroglobulinemia
Drug Class
Cyclophosphamide
Get full access now